EMMA — Emmaus Life Sciences, Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 822370 ·
Last close
$0.07
Market Cap
$4.76M
52W High
$0.09
52W Low
$0.01
ADV30
235,411
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 6,318,000 | 5,974,000 | 3,791,000 | 1,339,000 | 16,370,000 | 2,808,000 | 82,546,000 |
| Mar 2026 | 1,982,000 | 1,814,000 | -823,000 | -3,335,000 | 18,696,000 | 1,072,000 | 86,556,000 |
| Dec 2025 | 3,852,000 | 3,617,000 | 886,000 | -1,951,000 | 21,436,000 | 2,127,000 | 85,044,000 |
| Sep 2025 | 3,378,000 | 3,131,000 | 695,000 | -2,076,000 | 20,756,000 | 293,000 | 80,244,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-634,000
Investing CF
$2,171,000
Financing CF
$-1,782,000
CapEx
$-6,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.14
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-273,402,000
Inventory
$1,909,000
Receivables
$2,048,000
ST Investments
—
EBIT TTM
$-484,000
Pretax Income TTM
$-8,488,000
Interest Exp TTM
$8,004,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$15,530,000
EBITDA
$4,608,000
Free Cash Flow
$5,131,875
Enterprise Value
$31,329,714
Total Cash
$2,808,000
Total Debt
$30,516,000
Shares Out
70,188,263
Trailing EPS
$-0.10
Book Value
$-0.94
ROE
—
ROA
14.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 12,453,000 | 231,000 | -7,492,000 | 21,436,000 | 85,044,000 | -63,608,000 | -11,000 |
| Dec 2024 | 16,653,000 | -1,894,000 | -6,453,000 | 23,602,000 | 80,081,000 | -56,479,000 | -2,286,000 |
| Dec 2023 | 29,597,000 | 3,540,000 | -3,733,000 | 35,179,000 | 82,935,000 | -47,756,000 | -1,503,000 |
| Dec 2022 | 18,390,000 | -6,586,000 | -10,625,000 | 48,225,000 | 82,316,000 | -34,091,000 | -5,073,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.07
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PMHS | Polomar Health Services, Inc. | $4.82M | $0.17 | — |
| CANF | Can-Fite BioPharma Ltd. | $4.63M | $2.16 | — |
| ADXN | Addex Therapeutics Ltd. | $4.62M | $3.65 | — |
| ADTX | Aditxt, Inc. | $4.99M | $0.00 | — |
| ONCO | Onconetix, Inc. | $4.51M | $1.03 | — |
News headlines (Yahoo Finance, 1h cache)
Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer
2026-08-31 13:30 · Yahoo
Emmaus Life Sciences Reports Quarterly Financial Results
2026-08-14 20:11 · Yahoo
Emmaus, NIT sign Endari distribution agreement
2025-12-31 09:57 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.